| Size | Price | Stock |
|---|---|---|
| 100 mg | Get quote | |
| 250 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-117694 |
| M.Wt: | 572.61 |
| Formula: | C31H30F2N6O3 |
| Purity: | >98 % |
| Solubility: |
MK-8825 is an orally active, selective CGRP receptor antagonist with a Ki value of 47 pM for human CGRP receptors and 17 nM for rat CGRP receptors. MK-8825 blocks CGRP-stimulated cAMP responses and exhibits competitive-like antagonism. MK-8825 can be used in the research of migraine and temporomandibular joint disorders[1][2].
In Vitro:MK-8825 potently inhibits the binding of 125I-hCGRP to the native human CGRP receptor in SK-N-MC cells, with a Ki value of 0.052 nM[1].
MK-8825 potently inhibits the binding of 125I-hCGRP to rhesus monkey CGRP receptors, with a Ki value of 0.059 nM[1].
MK-8825 inhibits the binding of 125I-hCGRP to canine CGRP receptors, with a Ki value of 39 nM[1].
MK-8825 inhibits the binding of 125I-hCGRP to rabbit CGRP receptors, with a Ki value of 15 nM[1].
MK-8825 inhibits the binding of 125I-hCGRP to mouse CGRP receptors, with a Ki value of 19 nM[1].
MK-8825 potently blocks hCGRP-induced cAMP production in HEK293 cells expressing human CGRP receptors, with an IC50 of 0.23 nM[1].
MK-8825 inhibits the binding of human AM2 receptor with a Ki value of 590 nM[1].
MK-8825 inhibits the binding of human CT receptors with a Ki value of 3,200 nM[1].
MK-8825 inhibits the binding of human AMY1 receptor with a Ki value of 0.64 nM[1].
MK-8825 inhibits the binding of human AMY3 receptors with a Ki value of 1,100 nM[1].
In Vivo:MK-8825 (70 mg/kg; subcutaneous injection; single administration) significantly alleviates CFA (HY-153808)-induced acute orofacial nociceptive behaviors and trigeminal nucleus neuron activation in mice, without altering systemic IL-6 release[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.